Study S002445

Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05196958
Acronym: DiagMICI
Study type: INTERVENTIONAL
Masking: NONE
Status: UNKNOWN
Enrollment: 20
Start: 2022-01-25
Primary completion: 2024-01-14
Lead sponsor: Fondation Hôpital Saint-Joseph
Conditions: Inflammatory Bowel Diseases; Diabetes Mellitus, Type 2
Interventions: OTHER:GLP1 analogues
Results posted: FALSE

Registered primary outcomes

Glycemic control [Month 6]
Weight loss [Month 6]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018235	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. O'Neil PM, Lancet (London, England)	2018	Randomized trial	PMID 30122305 DOI	registry reference BACKGROUND:30122305
R0019848	Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Nauck M, Diabetes care	2009	Randomized trial	PMID 18931095 DOI	registry reference BACKGROUND:18931095
R0027293	Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Astrup A, Lancet (London, England)	2009	Randomized trial	PMID 19853906 DOI	registry reference BACKGROUND:19853906